Urothelial Carcinoma Clinical Trials
43 studies are recruiting for urothelial carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
By city
Studies now recruiting
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
This study will test whether enfortumab vedotin combined with pembrolizumab is an effective treatment for people with bladder cancer (urothelial carcinoma) involving the lymph nodes who are going to have surgery to remove their cancer (cystectomy). The researchers will look at whether treatment wit…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
- Locations
- 10 in total
- Run by
- Memorial Sloan Kettering Cancer Center
-
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
The goal of this clinical trial is to learn if a chemotherapy combination called gemcitabine and carboplatin (GC) works to treat advanced urothelial cancer in people who have already been treated with enfortumab vedotin and pembrolizumab (EVP). It will also learn about the efficacy and safety of GC…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Fox Chase Cancer Center, Philadelphia, Pennsylvania
- Locations
- 2 in total
- Run by
- Fox Chase Cancer Center
-
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey
- Locations
- 7 in total
- Run by
- Memorial Sloan Kettering Cancer Center
-
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Precision NextGen Oncology, Beverly Hills, California
- Locations
- 8 in total
- Run by
- Neonc Technologies, Inc.
-
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or metastatic solid tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York, New York
- Locations
- 13 in total
- Run by
- GI Innovation, Inc.
-
A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial
Prehabilitation refers to the process of improving a patient's functional capabilities prior to a surgical procedure with the goal of decreasing post-surgical inactivity and physical decline. This clinical trial evaluates the utility of a personalized home-based prehabilitation exercise interventio…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
- Run by
- University of Washington
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- University of Alabama Birmingham, Birmingham, Alabama
- Locations
- 26 in total
- Run by
- SystImmune Inc.
-
A Study of GEN1106 in Participants With Solid Tumors
The purpose of this trial is to learn about the safety and effectiveness of GEN1106 when it is used for the treatment of participants with certain types of cancer. The trial has multiple parts. The first part of the trial tests different doses of GEN1106 to find out if it is safe and determine what…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Yale Cancer Center, New Haven, Connecticut
- Locations
- 10 in total
- Run by
- Genmab
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- City of Hope National Medical Center, Duarte, California
- Locations
- 31 in total
- Run by
- Pfizer
-
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
This study will evaluate the efficacy and safety of UGN-104, a new formulation of UGN-101 (approved in the United States and Israel as JELMYTO [mitomycin] for pyelocalyceal solution), instilled in the upper urinary tract (UUT) of patients with low-grade upper tract urothelial cancer (LG-UTUC).
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Urology Centers of Alabama, Homewood, Alabama
- Locations
- 79 in total
- Run by
- UroGen Pharma Ltd.
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- University of Southern California, Los Angeles, California
- Locations
- 10 in total
- Run by
- Nammi Therapeutics Inc
-
DBC-664 in Adult Patients With Solid Tumors
DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian cancer, and other advanced solid tumors . This study is divided into 2…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Sarah Cannon Research Institute - Denver HealthONE, Denver, Colorado
- Locations
- 5 in total
- Run by
- Duboce Biopharmaceuticals, Inc.
-
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Locations
- 8 in total
- Run by
- Deciphera Pharmaceuticals, LLC
-
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with …
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Community Cancer Institute, Clovis, California
- Locations
- 47 in total
- Run by
- Bristol-Myers Squibb
-
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissues or other parts of the body. The purpose of the study is to…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Highlands Oncology Group, PA, Fayetteville, Arkansas
- Locations
- 153 in total
- Run by
- Pfizer
-
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medica…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Mayo Clinic in Florida, Jacksonville, Florida
- Run by
- Mayo Clinic
-
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- City of Hope, Duarte, California
- Locations
- 42 in total
- Run by
- Inhibrx Biosciences, Inc
-
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanc…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Banner Gateway Medical Center, Gilbert, Arizona
- Locations
- 221 in total
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
-
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer
This trial is a multi-site, single-arm, phase 2 trial of neoadjuvant combination of enfortumab vedotin and pembrolizumab in patients with high-grade localized/locally advanced cT1-4 N0-1 M0 upper tract urothelial cancer who are deemed eligible for curative-intent surgery (radical nephroureterectomy…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
- Locations
- 2 in total
- Run by
- University of Michigan Rogel Cancer Center
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Rocky Mountain Cancer Center, Littleton, Colorado
- Locations
- 28 in total
- Run by
- Jazz Pharmaceuticals
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult patients with selected squamous solid tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona
- Locations
- 41 in total
- Run by
- Alentis Therapeutics AG
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change i…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- University of California, Davis, Sacramento, California
- Run by
- University of California, Davis
-
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends an…
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Mayo Clinic in Florida, Jacksonville, Florida
- Run by
- Mayo Clinic
-
A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
The purpose of this study is to see how results of nerve tests change in people with urothelial cancer who receive treatment with enfortumab vedotin (EV)
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
- Locations
- 7 in total
- Run by
- Memorial Sloan Kettering Cancer Center
-
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
This substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045), Orange, California
- Locations
- 28 in total
- Run by
- Merck Sharp & Dohme LLC
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.